About Event

Welcome to the 13th Tumour Models London Summit!

Dedicated to Improving Target Selection, Facilitating Biomarker Discovery & Achieving
Clinical Translatability

Following an industry-wide shift to precision oncology marked by an influx of newly validated patient-derived, in vitro and ex vivo models and regulatory support for alternatives to animal testing, it is imperative to keep up to date with the latest tumour models. As assets only become more complex requiring more advanced testing and with development costs skyrocketing, it has never been more important to share cross-industry learnings in de-risking the move to the clinic.

Returning to London this December, the annual Tumour Models London Summit will be home to a community of 180+ industry experts leading Preclinical, Translational, Discovery, Toxicity, and Biology development teams eager to discuss best practices in optimising and implementing more translatable oncology models.

Covering cutting-edge case studies in validating new models, leveraging PDX, optimising forward and reverse translational studies and more from leading companies like AstraZeneca, Bicycle Therapeutics, Johnson & Johnson, Servier, and Gilead Sciences, this event is your one-stop-shop to learn about the latest innovations within the tumour modelling space as well as connect with a room full of your peers with the goal of closing the gap between research and patients.

Here's what you have to look forward to this December:

Complimentary Access for Drug Developers & Academics

Discover Cutting-Edge Tumor Models

Expand Your Network & Collaborate

Take advantage of free attendance to advance your translational studies and accelerate pipeline progression. This unique opportunity allows you to connect with leading model providers, helping you select the most suitable platforms for your research.

Stay ahead in your field by exploring the latest advancements in tumour models. Gain insights from case studies on a wide range of innovative models, including assessing a repertoire of 3D models, investigating PDX models for understanding resistance mechanisms, exploring 3D bioprinted bone mimics for cancer research and drug screening, and utilising novel GEMMs to study anti-tumour mechanisms.

With numerous networking opportunities, including a dedicated speed networking session, this summit is an essential platform to exchange challenges, share insights, and inspire solutions that enhance clinical confidence and relevance in tumour model research.

Complimentary Access for Drug Developers & Academics

Take advantage of free attendance to advance your translational studies and accelerate pipeline progression. This unique opportunity allows you to connect with leading model providers, helping you select the most suitable platforms for your research.

Discover Cutting-Edge
Tumor Models

Stay ahead in your field by exploring the latest advancements in tumour models. Gain insights from case studies on a wide range of innovative models, including assessing a repertoire of 3D models, investigating PDX models for understanding resistance mechanisms, exploring 3D bioprinted bone mimics for cancer research and drug screening, and utilising novel GEMMs to study anti-tumour mechanisms.

Expand Your Network & Collaborate

With numerous networking opportunities, including a dedicated speed networking session, this summit is an essential platform to exchange challenges, share insights, and inspire solutions that enhance clinical confidence and relevance in tumour model research.